

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
PROGRESS OF LEGAL PROCEEDING

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest updates in respect of the intellectual property protection efforts of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“**Biocytogen**”) against the Company’s patent entitled “Binding Molecule” (Patent Application No. CN201210057668.0, the “**Patent**”), the China National Intellectual Property Administration issued a final decision (the “**Decision**”) on June 5, 2025, upholding the Patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People’s Republic of China. The Patent covers a method for producing fully human heavy chain-only antibodies (“**HCAbs**”) utilizing transgenic animal.

The Decision affirms the Company’s rightful protections of its pioneering innovations and core intellectual property values. The Company will continue to leverage its patented HCAB technology in collaboration with its global partners to accelerate the development of transformative therapies and bring meaningful benefits to patients worldwide.

Cautionary Statement: There is no assurance that any products as stated in this announcement will ultimately be successfully developed and marketed by the Company or the collaboration partner. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 16 June 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.